Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Shares of Aytu BioPharma, Inc. (NASDAQ:AYTU) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.51 and traded as low as $1.20. Aytu BioPharma shares last traded at $1.20, with a volume of 21,489 shares trading hands.

Aytu BioPharma Trading Down 1.2 %

The company has a quick ratio of 0.81, a current ratio of 0.98 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $7.43 million, a price-to-earnings ratio of -0.83 and a beta of -1.63. The company has a 50-day moving average price of $1.51 and a 200-day moving average price of $1.82.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.28) earnings per share (EPS) for the quarter. Aytu BioPharma had a negative return on equity of 19.30% and a negative net margin of 7.62%.

Institutional Trading of Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC lifted its position in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 500,958 shares of the company’s stock after purchasing an additional 28,489 shares during the quarter. Aytu BioPharma accounts for 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest position. Stonepine Capital Management LLC owned about 8.15% of Aytu BioPharma worth $1,177,000 at the end of the most recent reporting period. 33.49% of the stock is currently owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.